Immunomedics, Inc. (IMMU) Reports Updated Results From Phase I Pretargeting Therapy Study in Colorectal Cancer
6/14/2012 10:17:57 AM
MIAMI BEACH, Fla., June 13, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that three studies involving two bispecific antibodies created by the Company's patented protein conjugation method, Dock-and-Lock (DNL), were presented at the 2012 Annual Meeting of the Society of Nuclear Medicine (SNM). All three presentations were pretargeting studies conducted by the Company's collaborators at the Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
comments powered by